癌症單株抗體市場規模、佔有率及成長分析（按類型、應用、最終用戶和地區分類）－2026-2033年產業預測

預計到 2024 年，癌症單株抗體市場規模將達到 1,036 億美元，到 2025 年將達到 1,226.6 億美元，到 2033 年將達到 4737.2 億美元，預測期（2026-2033 年）的複合年成長率為 18.4%。

抗癌單株抗體（mAb）作為癌症治療的重要組成部分，正日益受到重視，成為化療、放射線治療和手術等傳統療法的有力補充。在癌症發病率不斷上升、大量新核准獲批上市以及前景廣闊的新興治療方法的推動下，這類治療方法已展現出對固態腫瘤和骨髓惡性腫瘤的顯著療效。由於單株化療相比傳統化療副作用較少，其全球市場預計將持續成長。此外，醫療機構擴大採用經濟高效的生物相似藥單株抗體，也將進一步推動市場動態。儘管近年來癌症篩檢和治療可及性方面面臨諸多挑戰，但對有效癌症治療方法的強勁需求預示著單株抗體市場前景光明，並有望成為應對這一普遍疾病的關鍵解決方案。

癌症單株抗體市場促進因素

癌症單株抗體市場的成長主要受全球癌症發生率上升的推動，這使得人們迫切需要先進且有效的治療方法。由於單株抗體能夠精準靶向癌細胞，與傳統治療方法相比，它們通常能改善患者的治療效果並最大限度地減少副作用。這種對創新治療方法日益成長的需求不僅推動了研發投入，也反映了人們對癌症意識的不斷提高，從而促進了早期檢測。隨著人們認知的不斷提高，這些治療方法的市場也將隨之擴大，為癌症治療方法的進一步發展鋪路。

癌症單株抗體市場的限制

由於癌症單株抗體治療方法高成本，該市場面臨嚴峻的挑戰。這些成本源自於複雜的生產流程和龐大的研發投入。因此，獲得這些重要治療的機會可能有限，尤其是在低收入者和醫療預算有限的國家。這些治療方法的不可負擔性會給醫療服務提供者帶來沉重的負擔，並使醫療服務更難以提供。此外，高昂的價格通常意味著患者自付費用增加，進一步限制了他們獲得所需治療的能力，並最終阻礙了市場擴張和可及性。

癌症單株抗體市場趨勢

聯合治療的引入是癌症單株抗體市場的一大趨勢。這種創新方法將單株抗體與其他治療方法（例如免疫療法、標靶治療和化療）結合，以增強療效。透過同時靶向癌症生物學中的多個通路，聯合治療旨在降低抗藥性並改善患者預後。特別是，免疫查核點抑制劑與單株抗體的聯合應用體現了這項策略，能夠促進針對癌細胞的強效免疫反應。隨著人們對癌症治療複雜性的認知不斷加深，市場正朝著更個人化、多方面的治療方案發展，體現了致力於改善患者照護的決心。

目錄

介紹

• 調查目標
• 定義
• 市場覆蓋範圍

調查方法

• 資訊收集
• 二手和一手資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

前景
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 抑制因素
  • 任務
• 波特分析

關鍵市場考察

• 技術分析
• 價值鏈分析
• 市場生態系統
• 案例研究分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 競爭程度

按類型分類的癌症單株抗體市場

• 人性化
• 人類
• 嵌合體體
• 老鼠

按應用分類的癌症單株抗體市場

• 血癌
• 乳癌
• 肺癌
• 黑色素瘤
• 大腸直腸癌
• 肝癌
• 其他

按最終用戶分類的癌症單株抗體市場

• 醫院
• 研究所
• 其他

按地區分類的癌症單株抗體市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲（MEA）
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市佔率（2025 年）

主要企業簡介

• AbbVie Inc.（US）
• Amgen Inc.（US）
• Merck & Co., Inc.（US）
• Bristol-Myers Squibb Company（US）
• Gilead Sciences, Inc.（US）
• Takeda Pharmaceutical Company（Japan）
• AstraZeneca plc（UK）
• Eli Lilly and Company（US）
• Regeneron Pharmaceuticals, Inc.（US）
• BeiGene, Ltd（China）
• Biogen Inc.（US）
• Recordati Industria Chimica e Farmaceutica SpA（Italy）
• Pfizer（US）
• Spectrum Pharmaceuticals, Inc.（US）
• Iovance Biotherapeutics, Inc.（US）
• Exelixis, Inc.（US）
• OncoOne（US）
• CureVac AG（Germany）
• Cellerant Therapeutics, Inc.（US）
• Celltrion, Inc.（South Korea）
• Faron Pharmaceuticals Ltd.（Finland）

Cancer Monoclonal Antibodies Market size was valued at USD 103.6 Billion in 2024 and is poised to grow from USD 122.66 Billion in 2025 to USD 473.72 Billion by 2033, growing at a CAGR of 18.4% during the forecast period (2026-2033).

Cancer monoclonal antibodies (mAbs) are increasingly recognized as essential components in cancer treatment, complementing traditional approaches like chemotherapy, radiation, and surgery. This class of therapies has demonstrated significant effectiveness against both solid tumors and hematologic malignancies, propelled by rising cancer incidence, a robust pipeline of new approvals, and promising emerging therapies. The global market is set to expand as mAbs provide treatment options with fewer side effects compared to conventional chemotherapy. Additionally, the growing adoption of cost-effective biosimilar mAbs by healthcare providers will further enhance market dynamics. Despite recent challenges faced in cancer screening and treatment accessibility, the surging demand for effective cancer therapies indicates a favorable outlook for the monoclonal antibodies market as a critical solution against this pervasive disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Monoclonal Antibodies Market Segments Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Cancer Monoclonal Antibodies Market

The growth of the cancer monoclonal antibodies market is significantly driven by the rising incidence of cancer worldwide, leading to a pressing need for advanced and effective treatment options. Monoclonal antibodies offer precise targeting of cancer cells, often resulting in improved patient outcomes and minimized side effects compared to traditional treatments. This growing demand for innovative therapies not only stimulates investment in research and development but also reflects an increasing awareness of cancer that promotes early detection. As awareness continues to expand, so does the market for these therapies, paving the way for further advancements in cancer treatment approaches.

Restraints in the Cancer Monoclonal Antibodies Market

The Cancer Monoclonal Antibodies market faces significant challenges due to the elevated costs associated with these therapies. The expenses stem from complex manufacturing techniques and substantial research and development expenditures. As a result, access to these critical treatments may be restricted, particularly for low-income populations and nations with constrained healthcare budgets. The unaffordability of such therapies could place an enormous strain on healthcare providers, making it increasingly burdensome to deliver care. Additionally, the high prices often lead to increased out-of-pocket costs for patients, further limiting their ability to obtain necessary treatments and, ultimately, hindering market expansion and accessibility.

Market Trends of the Cancer Monoclonal Antibodies Market

The cancer monoclonal antibodies market is witnessing a significant trend toward the adoption of combination therapy. This innovative approach integrates monoclonal antibodies with other treatment modalities, including immunotherapies, targeted treatments, and chemotherapy, thereby enhancing therapeutic efficacy. By simultaneously targeting multiple pathways in cancer biology, combination therapies aim to reduce resistance and improve patient outcomes. Notably, the pairing of immune checkpoint inhibitors with monoclonal antibodies exemplifies this strategy, fostering robust immune responses against tumor cells. As the complexities of cancer treatment are increasingly acknowledged, the market is shifting toward more personalized and multifaceted therapeutic options, reflecting a commitment to advancing patient care.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cancer Monoclonal Antibodies Market by Type

• Market Overview
• Humanized
• Human
• Chimeric
• Murine

Cancer Monoclonal Antibodies Market by Application

• Market Overview
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

Cancer Monoclonal Antibodies Market by End-user

• Market Overview
• Hospitals
• Research Institutes
• Others

Cancer Monoclonal Antibodies Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoOne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CureVac AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faron Pharmaceuticals Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments